Astellas Email Format

Pharmaceutical Manufacturing
10,001+ employees
Tokyo, Japan

Astellas is a global pharmaceutical company that develops and delivers transformative therapies in oncology, ophthalmology, urology, immunology, and women's health to patients worldwide.

Find contacts at Astellas

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@astellas.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2005
Headquarters
Tokyo, Japan
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Naoki Okamura (Representative Director, President and Chief Executive Officer (CEO)), Atsushi Kitamura (Chief Financial Officer (CFO)), Claus Zieler (Chief Commercial & Medical Affairs Officer (CCMAO))

Tech Stack

Databricks

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Astellas?

Astellas uses the first.last format, so Jane Smith would be jane.smith@astellas.com.

What therapeutic areas does Astellas focus on?

Astellas focuses on oncology, ophthalmology, urology, immunology, and women's health. Its current portfolio includes strategic brands such as PADCEV for urothelial cancer, XTANDI for prostate cancer, IZERVAY for geographic atrophy, and VEOZAH for menopausal vasomotor symptoms.

Who leads Astellas as CEO in 2026?

Naoki Okamura serves as Representative Director, President and Chief Executive Officer of Astellas in 2026, with Atsushi Kitamura as CFO and Claus Zieler as Chief Commercial and Medical Affairs Officer.

Where is Astellas headquartered and how many employees does it have?

Astellas is headquartered in Tokyo, Japan, and employs approximately 12,349 people. Tools like Clay can help you find and verify specific Astellas contacts by role or region for outreach purposes.

How does Astellas use immuno-oncology and targeted protein degradation in its research strategy?

Astellas has identified immuno-oncology and targeted protein degradation as primary focus areas within its R&D strategy, alongside cell and gene therapy, as part of its 2026 Corporate Strategic Plan aimed at expanding its oncology pipeline beyond existing approved medicines.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles